Genetic Profiling Can Guide Stem Cell Transplantation for Patients With Myelodysplastic Syndromes

A single blood test and basic information about a patient's medical status can indicate which patients with myelodysplastic syndrome are likely to benefit from a stem cell transplant, and the intensity of pre-transplant chemotherapy and/or radiation therapy that is likely to produce the best results, according to new research from Dana-Farber Cancer Institute and Brigham and Women's Hospital.